Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients

Inclusion Criteria: * Korean Males and females aged 18 to 65 years. * Recipients of first, living unrelated or living related non-HLA identical donor kidney * Transplant, treated with cyclosporine microemulsion (Cs-ME) as primary immunosuppressant. * Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization. Effective contraception must be used during the trial and for 6 weeks following discontinuation of the study medication but at least for four months after randomization, even where there has been a history of infertility. Exclusion Criteria: * Second or subsequent kidney transplant or multi-organ recipients (e.g. kidney and pancreas) or previous transplant with any other organ. * Kidneys from cadaveric donors or HLA identical living related donors. * Patients with any known hypersensitivity to enteric coated Mycophenolate sodium (EC-MPS) or other components of the formulation (e.g. lactose). * Patients with thrombocytopenia (\< 75,000/mm3), with an absolute neutrophil count of \<1,500/mm3, and/or leukocytopenia (\<4,000/mm3 ), or hemoglobin \< 6g/dL . * Patients who have received any investigational drug within 30 days prior to study entry. * Patients with a history of malignancy within the last five years, except for successfully excised squamous or basal cell carcinoma of the skin. * Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use …